Clinical Trial Update: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2330811 in healthy subjects, with systemic sclerosis as the disease a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• GSK2330811 (GSK2330811)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Scleroderma, Systemic | Phase 1 | Status: COMPLETED